KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Gsk (GSK) EPS (Basic) (2016 - 2026)

Gsk has reported EPS (Basic) over the past 18 years, most recently at $0.0 for Q1 2026.

  • For Q1 2026, EPS (Basic) rose 6.96% year-over-year to $0.0; the TTM value through Mar 2026 reached $0.0, down 100.0%, while the annual FY2025 figure was $1.88, 131.38% up from the prior year.
  • EPS (Basic) for Q1 2026 was $0.0 at Gsk, up from $0.0 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $3.71 in Q4 2022 and troughed at -$0.0 in Q3 2024.
  • A 5-year average of $0.36 and a median of $0.0 in 2025 define the central range for EPS (Basic).
  • Biggest five-year swings in EPS (Basic): crashed 103.96% in 2024 and later skyrocketed 3568.12% in 2025.
  • Year by year, EPS (Basic) stood at $3.71 in 2022, then plummeted by 79.31% to $0.77 in 2023, then skyrocketed by 114.2% to $1.65 in 2024, then crashed by 100.0% to $0.0 in 2025, then soared by 173.11% to $0.0 in 2026.
  • Business Quant data shows EPS (Basic) for GSK at $0.0 in Q1 2026, $0.0 in Q4 2025, and $0.0 in Q3 2025.